Swiss pharmaceutical giant Novartis to divest its Alcon eye care devices business

The move is aimed at sharpening it focus on its prescription drugs business.

On Friday, Novartis disclosed its plans of divesting all of its assets from its Alcon eye care devices business as it sharpens its focus on prescription drugs.

The Basel, Switzerland-based multinational pharmaceutical company also shared it plan to launch a share buyback program of up to $5 billion.

Next Friday, Novartis is to hold a shareholder’s meeting wherein it aims to gain approval of its plan which has been scheduled for completion in the first half of 2019.

As for its shares buyback plan, it is scheduled to be completed by 2019.

Categories: Creativity, Entrepreneurship, HR & Organization, Strategy

Tags: , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: